Symphony IL-6 — NDA/BLA submission
2027
The Company's current plan is to complete analytical and clinical testing of the SYMON-II clinical trial samples by the end of 2026, with a goal of being in position to submit a 510(k) regulatory application to the FDA in 2027, with an objective of achieving FDA clearance thereafter.Source filing